The EPS projection of Quest Diagnostics Incorporated (NYSE:DGX) for quarter ended 2016-09-30 is $1.37. Last week, the EPS forecast was $1.37 against target of $1.37, a month earlier. Two months ago, this estimate was $1.37 versus forecast of $1.37 three months earlier, implying a deviation of 0%.
Quest Diagnostics Incorporated (NYSE:DGX) stated that 18 days ago, its stock price was positively revised 5 times while negative revisions were 3.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 2 , 3, 3, and 2, correspondingly.
EPS estimate downgrade for Quest Diagnostics Incorporated (NYSE:DGX) in the preceding 30, 120, 60 and 90 days were 0, 5, 2, and 7, correspondingly.
Quest Diagnostics Incorporated (NYSE:DGX) EPS target for the quarter closed 1 was $1.37, based on 11 recommendations. As reported on 2016-04-21 the EPS was $1.12. The change was $0, implying a percentage deviation of 0%. The projections showed a standard deviation of 0.02.
Quarterly Sales Estimates
Quest Diagnostics Incorporated (NYSE:DGX) yearly sales prediction for the fiscal 2017 stands at $1905.2 and the median estimate is at $1898.6. Almost 3 analysts issued sales target.
Highest sales target is $1926 while the lowest target is $1891 showing standard deviation of 18.409%.
As many as 3 analysts have sales targets revised upside while 3 reduced sales estimates, implying a deviation of 0%.
Last month, 3 revised sales number projection on upside while 3 lowered the sales projections, implying a deviation of -0.017%.
A quarter ago, 3 hiked sales target and 3 reduced sales forecast. Quest Diagnostics Incorporated (NYSE:DGX) announced that the deviation in forecast was -0.817%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...